Water-soluble phytin

Abstract

This phytin has improved solubility in water. The present application provides a phytin that contains calcium and / or magnesium at a specific mole ratio with respect to phytic acid.

Description

Water-soluble phytin

[0001] The present application relates to phytin having improved solubility in water and compositions containing same.

[0002] Phytic acid has chelating and antioxidant properties, and is also known to have anticoagulant properties, prevent hypercalciuria, and improve lipids. Furthermore, Patent Document 2 discloses that phytic acid inhibits purine nucleotide metabolism and phosphatase, and thus suppresses increases in serum uric acid levels in humans. Patent Document 2 also describes the blood pressure and blood glucose improving effects of phytic acid. Phytic acid is usually in a liquid state, but for easier processing, it is commercially available in the form of powdered phytic acid (phytic acid powder (50%)) in which excipients are added to phytic acid. However, this powdered phytic acid is deliquescent and unstable, so stabilization efforts have been made, such as a stabilized powdered phytic acid composition in which phytic acid is intimately attached to sodium acetate powder (Patent Document 3). On the other hand, phytin, a mineral salt of phytic acid such as calcium and magnesium, is commercially available in powder form, but it is stable and does not deliquesce. Phytin is a general term for mineral salts, and does not mean that the types or molar ratios of mineral components such as calcium and magnesium are constant, and in fact, the molar ratios of mineral components such as magnesium and calcium in naturally occurring phytin in rice, corn, wheat, oats, etc. are not constant (Non-Patent Document 1). Phytin is expected to have various pharmacological / health-promoting effects due to its constituent phytic acid, but all of the phytins known to date are insoluble in water (Non-Patent Document 2), making them unsuitable for use in preparations requiring good water solubility, such as liquid preparations and granules that are dissolved in water before use and ingested.

[0003] JP 2017-39762 A International Publication No. 2019 / 082335 JP 2012-213380 A

[0004] Yoshida KT, Wada T, Koyama H, Mizobuchi-Fukuoka R, Naito S. Temporal and spatial patterns of accumulation of the transcript of Myo-inositol-1-phosphate synthase and phytin-containing particles during seed development in rice. Plant Physiol. 1999;119(1):65‐72.Plimmer RH, et al., Biochem J. 1913;7(2):157-74.

[0005] The disclosures of all prior art documents cited in this specification are incorporated herein by reference.

[0006] An object of the present invention is to provide phytin having improved solubility in water, a method for producing the same, and a composition containing the phytin.

[0007] The present inventors have conducted extensive research to solve the above problems and have surprisingly found that phytin having a molar ratio of magnesium and calcium to phytic acid within a specific range has extremely high solubility in water, thereby completing the present invention. Furthermore, they have also surprisingly found that, although existing commercially available water-insoluble phytin has a lower inhibitory activity against purine nucleotide metabolism than phytic acid, phytin having a molar ratio of magnesium and calcium to phytic acid within a specific range has a higher inhibitory activity against purine nucleotide metabolism than the commercially available water-insoluble phytin, and has activity equal to or greater than that of phytic acid.

[0008] The present disclosure provides the following inventive aspects.

[0009] [1] A water-soluble phytin containing (A) calcium and / or (B) magnesium. [2] The phytin according to [1], wherein, when the amount of substance of (A) calcium is x moles and the amount of substance of (B) magnesium is y moles per 1.8 moles of phytic acid, 1.4x + y ≦ 5.4 (e.g., 0.5 ≦ 1.4x + y ≦ 5.4, 0.8 ≦ 1.4x + y ≦ 5.4, 1 ≦ 1.4x + y ≦ 5.4) (x ≧ 0, y ≧ 0, provided that x and y are not both 0). [3] Phytin containing (A) calcium and / or (B) magnesium, wherein, when the amount of (A) calcium is x moles and the amount of (B) magnesium is y moles per 1.8 moles of phytic acid, 0≦x≦2 (e.g., 0.5≦x≦1.5), 0≦y≦6 (e.g., 0.5≦y≦5.5, 1≦y≦4.5), and x and y are not both 0. [4] Phytin according to [2] or [3], wherein x + y > 0.5 (e.g., x + y ≧ 1.0). [5] Phytin according to any one of [2] to [4], wherein 0.3≦x≦1.07 and 3.9≦y≦4.98. [6] Phytin according to any one of [2] to [5], wherein 0.65≦x≦1.07 and 3.9≦y≦4.4. [7] Phytin according to any one of [3] to [4], wherein 0.9≦x≦1.1 and 3.9≦y≦4.1. [8] Phytin according to any one of [1] to [7], further containing (C) potassium and / or (D) sodium. [9] Phytin according to [8], wherein, when the amount of substance of (C) potassium is pmoles and the amount of substance of (D) sodium is q moles per 1.8 moles of phytic acid, 0≦p≦4 (e.g., 0.5≦p≦3, 0.5≦p≦2, 0.5≦p≦1.5, 0.5≦p≦1.2) and 0≦q≦6 (e.g., 0.5≦q≦3, 0.5≦q≦2, 0.5≦q≦1.5, 0.5≦q≦1.2), and both p and q are not 0.

[10] A composition containing phytin according to any one of [1] to [9].

[11] A purine absorption inhibitory composition containing the phytin according to any one of [1] to [9].

[12] The purine absorption inhibitory composition according to

[11] , wherein the purine is absorbed from the intestinal tract.

[13] A composition for inhibiting purine nucleotide metabolism, comprising the phytin according to any one of [1] to [9].

[14] A composition for inhibiting phosphatase, comprising the phytin according to any one of [1] to [9].

[15] A composition for suppressing an increase in uric acid level, comprising the phytin according to any one of [1] to [9].

[16] A composition for improving blood pressure, comprising the phytin according to any one of [1] to [9].

[17] A composition for improving blood sugar level, comprising the phytin according to any one of [1] to [9].

[18] A composition for preventing hypercalciuria, comprising the phytin according to any one of [1] to [9].

[19] A lipid-improving composition, comprising the phytin according to any one of [1] to [9].

[20] The composition according to any one of

[10] to

[19] , which is a solid formulation (e.g., powder, granules, tablets, or pills).

[21] Phytic acid in the presence of water and a calcium source (e.g., Ca(OH) ２ ) and a magnesium source (e.g., Mg(OH) ２

[22] A method for improving the solubility of phytin in water, comprising adding a calcium source (e.g., Ca(OH)), wherein, when the amount of (A) calcium is x moles and the amount of (B) magnesium is y moles per 1.8 moles of phytic acid, 1.4x + y ≦ 5.4 (e.g., 0.5 ≦ 1.4x + y ≦ 5.4, 0.8 ≦ 1.4x + y ≦ 5.4, 1 ≦ 1.4x + y ≦ 5.4) (x ≧ 0, y ≧ 0, with the proviso that neither x nor y is 0). ２ ) and / or a magnesium source (e.g., Mg(OH) ２ ) in the presence of water, and a drying step of drying the resulting mixture, wherein, when the amount of substance of (A) calcium is x moles and the amount of substance of (B) magnesium is y moles per 1.8 moles of phytic acid in the mixture, 1.4x + y ≦ 5.4 (e.g., 0.5 ≦ 1.4x + y ≦ 5.4, 0.8 ≦ 1.4x + y ≦ 5.4, 1 ≦ 1.4x + y ≦ 5.4) (x ≧ 0, y ≧ 0, with the proviso that neither x nor y is 0).

[23] A method for producing phytin, comprising: a mixing step of mixing phytic acid; and a magnesium source (e.g., Mg(OH) ２ ) and / or a calcium source (e.g., Ca(OH)２ ) in the presence of water, and a drying step of drying the resulting mixture, wherein, in the mixture, when the amount of substance of (A) calcium is x moles and the amount of substance of (B) magnesium is y moles per 1.8 moles of phytic acid, 0≦x≦2 (e.g., 0.5≦x≦1.5), 0≦y≦6 (e.g., 0.5≦y≦5.5, 1≦y≦4.5), and x and y are not both 0.

[24] The method according to any one of

[21] to

[23] , wherein x + y > 0.5 (e.g., x + y ≧ 1.0).

[25] The method according to any one of

[21] to

[24] , wherein 0.3≦x≦1.07 and 3.9≦y≦4.98.

[26] The method according to any one of

[21] to

[25] , wherein 0.65≦x≦1.07 and 3.9≦y≦4.4.

[27] The method according to

[23] , wherein 0.9≦x≦1.1 and 3.9≦y≦4.1.

[28] In the mixing step, phytic acid; and a magnesium source (e.g., Mg(OH) ２ ) and / or a calcium source (e.g., Ca(OH) ２

[29] The method according to any one of

[22] to

[27] , wherein the above ingredients are mixed in the presence of water and an excipient.

[29] In the mixing step, phytic acid; a magnesium source (e.g., Mg(OH) ２ ) and / or a calcium source (e.g., Ca(OH) ２ ), and a potassium source (e.g., KOH) and / or a sodium source (e.g., NaOH) are mixed in the presence of water.

[30] In the mixing step, phytic acid; a magnesium source (e.g., Mg(OH) ２ ) and / or a calcium source (e.g., Ca(OH) ２), and a potassium source (e.g., KOH) and / or a sodium source (e.g., NaOH): are mixed in the presence of water and an excipient.

[31] The method according to any one of

[22] to

[29] , wherein, in the mixture, when the amount of substance of (C) potassium is p moles and the amount of substance of (D) sodium is q moles per 1.8 moles of phytic acid, 0≦p≦4 (e.g., 0.5≦p≦3, 0.5≦p≦2, 0.5≦p≦1.5, 0.5≦p≦1.2) and 0≦q≦6 (e.g., 0.5≦q≦3, 0.5≦q≦2, 0.5≦q≦1.5, 0.5≦q≦1.2), and both p and q are not 0.

[32] The method according to any one of

[28] ,

[30] , and

[31] , wherein the excipient is selected from dextrin, starches, cellulose, sugars (e.g., lactose, sucrose, trehalose), and any combination thereof.

[33] A purine absorption inhibitory composition comprising water-soluble phytin containing only calcium as a mineral component.

[34] The purine absorption inhibitory composition according to

[33] , wherein the molar ratio of phytic acid to calcium in the water-soluble phytin is 1.8:0.1 to 4.0 (molar).

[35] Use of phytin according to any one of [1] to [9] in the production of a purine absorption inhibitory composition, a purine nucleotide metabolism inhibitory composition, a phosphatase inhibitory composition, a composition for inhibiting uric acid level elevation, a blood pressure improving composition, a blood glucose level improving composition, a liver function improving composition, a serum iron regulating composition, a calcium absorption promoting composition, a hypercalciuria preventing composition, or a lipid improving composition.

[36] A method for suppressing purine absorption, inhibiting purine nucleotide metabolism, inhibiting phosphatase, suppressing an increase in uric acid level, improving blood pressure, improving blood glucose level, improving liver function, regulating serum iron, or promoting calcium absorption, preventing hypercalciuria, improving lipid levels, or preventing deterioration of lipid levels, comprising administering the composition containing phytin according to any one of [1] to [9].

[37] Phytin according to any one of [1] to [9] for use in suppressing purine absorption, inhibiting purine nucleotide metabolism, inhibiting phosphatase, suppressing uric acid level elevation, improving blood pressure, improving blood glucose level, improving liver function, regulating serum iron, promoting calcium absorption, preventing hypercalciuria, or improving lipids. Any two or more of the components of [1] to

[37] above can be selected and combined.

[0010] The present invention provides phytin having improved solubility in water, a method for producing the same, and a composition containing the phytin.

[0011] Figure 1 shows the solubility test results for Test Example 1. The horizontal axis shows the molar ratio of Ca to 1.8 moles of phytic acid. The vertical axis shows the molar ratio of Mg to 1.8 moles of phytic acid. Figure 2-1 shows the results of the purine nucleotide metabolism inhibitory activity test for Test Example 2. Each column shows the mean ± standard error, and an asterisk indicates P<0.05 (vs. PA, unpaired t-test). Figure 2-2 shows the results of the purine nucleotide metabolism inhibitory activity test for Test Example 2. Each column shows the mean ± standard error, and an asterisk indicates P<0.05 (vs. PA, unpaired t-test). Figure 2-3 shows the results of the purine nucleotide metabolism inhibitory activity test for Test Example 2. Each column shows the mean ± standard error, and an asterisk indicates P<0.05 (vs. PA, unpaired t-test). Figure 2-4 shows the results of the purine nucleotide metabolism inhibitory activity test for Test Example 2. Each column shows the mean ± standard error, and an asterisk indicates P<0.05 (vs. PA, unpaired t-test). Figures 2-5 show the results of the purine nucleotide metabolism inhibitory activity test in Test Example 2. Each column shows the mean ± standard error, and an asterisk indicates P<0.05 (vs. PA, unpaired t-test). Figure 3 shows the results of the stability (deliquescense) test of commercial products (powdered phytic acid and phytin) in Test Example 3. Top row: powdered phytic acid. Bottom row: phytin.

[0012] Hereinafter, embodiments of the present invention will be described in detail.

[0013] In one aspect, the present invention provides phytin containing (A) calcium and / or (B) magnesium and having improved solubility in water (hereinafter, sometimes referred to as the phytin of the present invention).

[0014] In this disclosure, "phytin" refers to a mineral salt of phytic acid, a hexaphosphate ester of myo-inositol, containing magnesium, calcium, or both of these minerals. The minerals may further include potassium, sodium, etc.

[0015] In the present disclosure, "phytin with improved water solubility" may refer to phytin with improved water solubility compared to phytin containing mineral components in a molar ratio of Mg:K:Na:Ca = 18.5:2.4:2:1 (mol) per 1.8 moles of phytic acid (this phytin has been known to be water-insoluble). The method for testing water solubility is not particularly limited. For example, it may refer to phytin for which no turbidity or precipitation is visually observed when tested by the method of Test Example 1 in the Examples of the present application. Alternatively, it may refer to phytin for which no precipitation is visually observed when phytin (10 mg / ml) is added to water (20-25°C), vortexed for 30 seconds, and sonicated for 60 seconds, a mixing procedure repeated three times. The phytin with improved water solubility of the present invention may contain other mineral components (e.g., potassium and sodium) in addition to calcium and magnesium, as long as the phytin exhibits improved water solubility.

[0016] In one embodiment, the phytin of the present invention is a water-soluble phytin.

[0017] In the present disclosure, "water-soluble phytin" refers to phytin that is soluble in water. For example, "water-soluble phytin" may refer to phytin that, when phytin (10 mg / ml) is added to water (20-25°C), vortexed for 30 seconds, and sonicated for 60 seconds, the mixture is mixed three times, and the optical density (OD) at 600 nm is measured using a spectrophotometer, the OD600 value is 0.008 or less, and no turbidity or precipitation is visually observed. Alternatively, it may refer to phytin that, when tested using the method of Test Example 1 in the Examples of the present application, the OD600 value is 0.008 or less, and no precipitation is visually observed. The water-soluble phytin of the present invention may contain other mineral components (e.g., potassium and sodium) in addition to calcium and magnesium, as long as the phytin is water-soluble.

[0018] In one embodiment, the phytin of the present invention contains (A) calcium and / or (B) magnesium, and when the amount of substance of (A) calcium per 1.8 moles of phytic acid is x moles and the amount of substance of (B) magnesium per 1.8 moles of phytic acid is y moles, 0≦x≦2, 0≦y≦6, and neither x nor y is 0.

[0019] In one embodiment, the phytin of the present invention contains (A) calcium and / or (B) magnesium, and when the amount of substance of (A) calcium per 1.8 moles of phytic acid is x moles and the amount of substance of (B) magnesium per 1.8 moles of phytic acid in the phytin, the relationship is 1.4x + y ≦ 5.4 (x ≧ 0, y ≧ 0, provided that x and y are not both 0).

[0020] In one embodiment, the phytin of the present invention further contains (C) potassium and / or (D) sodium.

[0021] In one embodiment, the phytin of the present invention further contains (C) potassium and / or (D) sodium, and when the amount of substance of (C) potassium per 1.8 moles of phytic acid in the phytin is p moles and the amount of substance of (D) sodium is q moles, 0≦p≦4, 0≦q≦6, and both p and q are not 0.

[0022] The table below shows the amount of magnesium and calcium per 1.8 moles of phytic acid in natural phytin contained in each plant, calculated based on the disclosure in Non-Patent Document 2 (Plimmer RH, et al., Biochem J. 1913;7(2):157-74). Generally, conventional phytin has the physical properties of being a white, water-insoluble neutral powder, which is non-deliquescent and has excellent stability.

[0023] In one embodiment, the phytin of the present invention is not the phytin contained in wheat.

[0024] In one embodiment, the phytin of the present invention is not phytin contained in natural products (e.g., wheat, corn, oats, rice).

[0025] The method for producing phytin of the present invention is not particularly limited, but for example, it can be produced by the production method described below as one embodiment of the present invention.

[0026] In one aspect, the present invention provides a method for producing phytin (hereinafter, sometimes referred to as the production method of the present invention), comprising: a mixing step of mixing phytic acid; and a magnesium source and / or a calcium source; in the presence of water; and a drying step of drying the resulting mixture.

[0027] In one embodiment of the production method of the present invention, when the amount of (A) calcium per 1.8 moles of phytic acid contained in the mixture is x moles and the amount of (B) magnesium per 1.8 moles of phytic acid is y moles, the relationship 1.4x + y ≦ 5.4 (x ≧ 0, y ≧ 0, provided that neither x nor y is 0).

[0028] In one embodiment of the manufacturing method of the present invention, when the amount of (A) calcium per 1.8 moles of phytic acid contained in the mixture is x moles and the amount of (B) magnesium per 1.8 moles of phytic acid is y moles, 0≦x≦2, 0≦y≦6, and neither x nor y is 0.

[0029] In one embodiment of the production method of the present invention, the mixing step further includes a potassium source and / or a sodium source.

[0030] The method for producing phytic acid used in the production method of the present invention is not particularly limited. For example, phytic acid may be synthesized using organic chemistry or microorganisms, or it may be extracted, partially purified, or processed from plants, microorganisms, or various foods and beverages containing phytic acid. Phytic acid isolated from these extracts, partially purified, or processed products may also be used. Phytic acid may be prepared in advance as an aqueous solution and then mixed with other raw materials.

[0031] In the mixing step of the production method of the present invention, the concentration of phytic acid contained in the mixture is not particularly limited, but is, for example, contained at 0.01 to 2.0 μmol / mL (preferably 0.25 to 1.0 μmol / mL) as phytic acid.

[0032] In this disclosure, a magnesium source refers to a magnesium source that is ２＋ In the production method of the present invention, the magnesium source may be mixed with other raw materials either as it is or in the form of an aqueous solution in advance.

[0033] In one embodiment of the process of the present invention, the magnesium source is Mg(OH). ２ is.

[0034] In the present disclosure, a calcium source is a calcium source that is ２＋ In the production method of the present invention, the calcium source may be mixed with other raw materials either as it is or in the form of an aqueous solution in advance.

[0035] In one embodiment of the process of the present invention, the calcium source is Ca(OH). ２ is.

[0036] In this disclosure, a potassium source is a potassium source in water ＋ In the production method of the present invention, the potassium source may be mixed with other raw materials either as it is or in the form of an aqueous solution in advance.

[0037] In one embodiment of the process of the present invention, the potassium source is KOH.

[0038] In this disclosure, a sodium source is a source of Na in water. ＋ In the production method of the present invention, the sodium source may be mixed with other raw materials either as it is or in the form of an aqueous solution in advance.

[0039] In one embodiment of the process of the present invention, the sodium source is NaOH.

[0040] In one embodiment of the manufacturing method of the present invention, the mixing step is carried out in the presence of water and an excipient. The amount of the excipient is not particularly limited, but for example, the mixture is mixed at a weight ratio of phytic acid:excipient=1:0.1 to 3.0 (preferably 0.8 to 1.6, more preferably 1.1 to 1.4). The excipient used is preferably one that acts suitably to maintain phytin in a powder state.

[0041] In one embodiment of the production method of the present invention, the "excipient" may be dextrin, starches (e.g., potato starch, corn starch), cellulose, or sugars (e.g., lactose, sucrose, trehalose). One type of excipient may be used, or multiple types of excipients may be used.

[0042] In one embodiment of the manufacturing method of the present invention, the excipient is dextrin.

[0043] In one embodiment of the production method of the present invention, the pH of the mixture is 3.0 to 5.0 (preferably 3.5 to 4.5, more preferably 3.8 to 4.2), and can be adjusted appropriately with HCl or the like.

[0044] In one embodiment of the production method of the present invention, the mixing time in the mixing step is not particularly limited, and mixing is preferably continued until a clear solution is obtained, for example, for 1 to 1.5 hours.

[0045] The drying method in the drying step of the production method of the present invention is not particularly limited, and can be a method commonly used in the field (for example, freeze-drying).

[0046] In addition to the mixing step and the drying step, the production method of the present invention may include further steps such as filtration, pulverization, etc. In the production method of the present invention, further additives may be added within a range that does not affect the solubility of phytin.

[0047] Hereinafter, phytin produced by the production method of the present invention may also be referred to as phytin of the present invention.

[0048] In one embodiment of the present invention, the phytin of the present invention contains calcium (A) and / or magnesium (B) in a predetermined ratio. The contents of calcium (A) and magnesium (B) are not particularly limited as long as the effects of the present invention, such as improved solubility, are achieved. For example, the amounts of calcium (A) and magnesium (B) per 1.8 moles of phytic acid contained in phytin, where x and y are the respective amounts of the substances, satisfy the following formula: 1.4x + y ≦ 5.4 (x ≧ 0, y ≧ 0, provided that neither x nor y is 0). More preferably, the ranges are 0.3 ≦ x ≦ 1.07 and 3.9 ≦ y ≦ 4.98.

[0049] In one embodiment of the present invention, 0.5≦y≦5.4.

[0050] In one embodiment of the present invention, 0.5≦y≦5.

[0051] In one embodiment of the present invention, 1≦y≦4.5.

[0052] In one embodiment of the present invention, 3.9≦y≦4.98.

[0053] In one embodiment of the present invention, 3.9≦y≦4.4.

[0054] In one embodiment of the present invention, 3.9≦y≦4.1.

[0055] In one embodiment of the present invention, 0.3≦x≦3.8.

[0056] In one embodiment of the present invention, 0.5≦x≦1.5.

[0057] In one embodiment of the present invention, 0.3≦x≦1.07.

[0058] In one embodiment of the present invention, 0.65≦x≦1.07.

[0059] In one embodiment of the present invention, 0.9≦x≦1.1.

[0060] In one embodiment of the present invention, the range of y excludes 4.5≦(or <) y≦(or <) 5.

[0061] In one embodiment of the present invention, 0.5≦1.4x+y≦5.4 (x≧0, y≧0, provided that x and y are not both 0).

[0062] In one embodiment of the present invention, 0.8≦1.4x+y≦5.4 (x≧0, y≧0, provided that x and y are not both 0).

[0063] In one embodiment of the present invention, 1≦1.4x+y≦5.4 (x≧0, y≧0, provided that x and y are not both 0).

[0064] In one embodiment of the present invention, 2.5≦1.4x+y≦5.4 (x≧0, y≧0, provided that x and y are not both 0).

[0065] In one embodiment of the present invention, 0.5≦p≦3.

[0066] In one embodiment of the present invention, 0.5≦p≦2.

[0067] In one embodiment of the present invention, 0.5≦p≦1.5.

[0068] In one embodiment of the present invention, 0.5≦p≦1.2.

[0069] In one embodiment of the present invention, 0.8≦p≦1.2.

[0070] In one embodiment of the present invention, 0.5≦q≦3.

[0071] In one embodiment of the present invention, 0.5≦q≦2.

[0072] In one embodiment of the present invention, 0.5≦q≦1.5.

[0073] In one embodiment of the present invention, 0.5≦q≦1.2.

[0074] In one embodiment of the present invention, 0.8≦q≦1.2.

[0075] In one embodiment, a composition containing the phytin of the present invention (hereinafter sometimes referred to as the composition of the present invention) is provided. By using the phytin of the present invention, a composition such as a powder with improved solubility in water can be provided. Because the phytin of the present invention can have enzyme inhibitory activity equal to or greater than that of phytic acid, it can be used as a substitute for phytic acid in phytic acid-containing compositions. Phytin has a long history of use in food, is a highly safe substance, and is suitable for long-term, continuous intake. According to the present invention, by forming it into a solid composition such as a powder composition, portability is improved, increasing convenience, and making it possible to take it for a longer period of time and continuously.

[0076] In one embodiment, the phytin of the present invention may also be non-deliquescent. Due to the deliquescent nature of phytic acid, the storage stability is low, making it difficult to use in solid preparations. In contrast, the non-deliquescent phytin of the present invention has excellent storage stability and may have activity equivalent to or greater than that of phytic acid. Therefore, it may be suitable for use as a substitute for phytic acid, particularly in solid preparations (e.g., powders, granules, tablets, pills, etc.) that are difficult to formulate with phytic acid due to its deliquescent nature.

[0077] In one embodiment of the present invention, from the viewpoint of deliquescence, x+y>0.1, preferably x+y>0.3, more preferably x+y>0.5, and even more preferably x+y≧1.0.

[0078] In one embodiment of the present invention, from the viewpoint of purine nucleotide metabolism inhibitory activity, 0≦y≦6, more preferably 0≦y≦5, and even more preferably 0≦y≦4.5.

[0079] In one embodiment of the present invention, from the viewpoint of purine nucleotide metabolism inhibitory activity, y satisfies 0.5≦y≦6, more preferably 0≦y≦5, and even more preferably 0≦y≦4.5.

[0080] In one embodiment of the present invention, from the viewpoint of purine nucleotide metabolism inhibitory activity, 0≦x≦2, more preferably 0.5≦x≦1.5.

[0081] In one embodiment of the present invention, 1.4x+y≦5.4, 0.9≦x≦1.1, 3.9≦y≦4.1, 0.8≦p≦1.2, and 0.8≦q≦1.2.

[0082] In one embodiment of the invention, x=1, y=4, p=1, and q=1.

[0083] In one embodiment of the present invention, from the viewpoint of purine nucleotide metabolism inhibitory activity, the phytin of the present invention is a water-soluble phytin that does not contain magnesium as a mineral component. In one embodiment of the present invention, y=0.

[0084] In one embodiment of the present invention, the phytin of the present invention is a water-soluble phytin containing only calcium as a mineral component. From the viewpoint of purine nucleotide metabolism inhibitory activity, the ratio of phytic acid:calcium is preferably 1.8:0.1 to 4.0 (mol).

[0085] In one embodiment, a purine absorption inhibiting composition, a purine nucleotide metabolism inhibiting composition, a phosphatase inhibiting composition, a uric acid level increase inhibiting composition, a blood pressure improving composition, a blood glucose level improving composition, a liver function improving composition, a serum iron regulating composition, or a calcium absorption promoting composition is provided, which contains the phytin of the present invention.

[0086] In one embodiment, the present invention provides a method for suppressing purine absorption, inhibiting purine nucleotide metabolism, inhibiting phosphatase, suppressing elevated uric acid levels, improving blood pressure, improving blood glucose levels, improving liver function, regulating serum iron, or promoting calcium absorption, which method comprises administering a composition containing phytin of the present invention (e.g., a solid composition (e.g., powder, granules)).

[0087] <Other Components> The phytin of the present invention may contain mineral components other than calcium (A) and magnesium (B) to the extent that the effects of the present invention are not impaired. In one embodiment, the phytin of the present invention is substantially free of mineral components other than calcium, magnesium, potassium, and sodium.

[0088] <Phytin Dosage> The amount of phytin contained in the composition of the present invention (food, beverage, pharmaceutical composition, etc.), the amount of phytin administered per administration, and the amount of phytin administered per day are not particularly limited as long as the desired effect is achieved, and can be appropriately selected depending on the form of the composition, the number of administrations, the health condition of the subject, etc. The administration period of the composition of the present invention is not particularly limited as long as the desired effect is achieved, and may be administered once or continuously. For example, in order to continuously obtain effects such as purine absorption inhibition, purine nucleotide metabolism inhibition, phosphatase inhibition, suppression of uric acid level increase, blood pressure improvement, blood glucose level improvement, liver function improvement, serum iron regulation, or calcium absorption promotion, the composition of the present invention is preferably ingested continuously for a long period of time, for example, 2 days, 3 days, 1 week, 10 days, 1 month, or 3 months or more.

[0089] <Phytin Content in Composition> The amount of phytin to be incorporated into the composition of the present invention varies depending on the type of phytin, the form of the composition, etc., but can generally be selected appropriately from the range of 0.1 to 90% by weight of phytin relative to the total weight of the composition. Examples include 0.5 to 90% by weight, 0.5 to 85% by weight, 0.5 to 80% by weight, 1 to 70% by weight, and 1 to 50% by weight. Further examples of upper limits for the phytin content of the composition of the present application include 90% by weight, 85% by weight, 80% by weight, 70% by weight, 50% by weight, 30% by weight, 10% by weight, and 5% by weight, based on the total weight of the composition. Further examples of lower limits for the phytin content of the composition of the present application include 0.1% by weight, 0.5% by weight, 0.7% by weight, and 1% by weight, based on the total weight of the composition. A preferred range of the amount of phytin to be incorporated into the composition of the present application can be represented by a combination of the upper and lower limits. When the composition of the present application is formulated as a solid preparation such as a tablet, granule, capsule, powder, or chewable tablet, the amount of phytin to be incorporated into the composition of the present application can be appropriately selected, for example, from the range of 1 to 90% by weight, based on the total weight of the composition. Preferred examples include 1 to 90% by weight, 5 to 80% by weight, 10 to 70% by weight, and 50 to 70% by weight.

[0090] When the composition of the present invention is formulated as a solid preparation such as a tablet, granule, capsule, powder, or chewable tablet, further examples of the upper limit of the phytin content in the composition of the present invention include, preferably, 90 wt %, 85 wt %, 80 wt %, 70 wt %, and 50 wt % relative to the total weight of the composition; further examples of the lower limit of the phytin content in the composition of the present invention include, preferably, 1 wt %, 5 wt %, 10 wt %, and 20 wt % relative to the total weight of the composition; a preferred range of the amount of phytin to be incorporated in the composition of the present invention can be represented by a combination of the upper and lower limits. The composition of the present invention varies depending on the type of phytin, but phytin can be administered in an amount of, for example, 10 mg to 15 g, preferably 100 mg to 8 g, and more preferably 300 mg to 5 g, of phytic acid per dose. Examples of lower limit values ​​for the amount of phytin ingested per serving include 10 mg, 100 mg, 300 mg, 500 mg, and 600 mg of phytic acid, and examples of upper limit values ​​include 15 g, 10 g, 8 g, 5 g, 3 g, 2 g, 1 g, and 600 mg of phytic acid, and a preferred range of the amount of phytin ingested per serving can be represented by a combination of the upper limit value and the lower limit value.

[0091] In the composition of the present invention, phytin may be administered in an amount of, for example, 10 mg to 15 g, preferably 100 mg to 8 g, and more preferably 300 mg to 5 g of phytic acid per day, although this varies depending on the type of phytin. Examples of lower limits for the daily intake of phytin include 10 mg, 100 mg, 300 mg, 500 mg, and 600 mg of phytic acid, and examples of upper limits for phytic acid include 15 g, 10 g, 8 g, 5 g, 3 g, 2 g, 1 g, and 600 mg. A preferred range of the daily intake of phytin can be represented by a combination of the upper and lower limits. The amount of phytin administered per day may be administered in a single dose or in multiple doses (e.g., two, three, four, or five times).

[0092] <Analysis Method> The phytin content in the composition of the present invention can be analyzed by a general analysis method known to those skilled in the art, including, but not limited to, ion chromatography and vanadomolybdic acid absorbance method.

[0093] <Timing of Ingestion> There are no particular limitations on the timing of ingestion of the composition of the present invention, but it is preferable to ingest it with a meal or within 30 minutes before or after a meal.

[0094] <Types of Orally Ingested Preparations> The composition of the present invention is preferably formulated as an orally ingested preparation, and the formulation type is not particularly limited, but may be, for example, tablets, granules, capsules, powders, chewable tablets, confectioneries (cookies, biscuits, chocolate confectioneries, chips, cakes, gum, candies, gummy candies, steamed buns, yokan, puddings, jellies, yogurt, ice cream, sherbet, etc.), bread, noodles, rice products, cereal foods, powdered drinks, soups (powdered, freeze-dried), miso soup (powdered, freeze-dried), or ordinary food forms.

[0095] The composition of the present invention can be formulated into an orally ingestible preparation by adding, in addition to phytin, a pharmaceutically acceptable base or carrier, an additive usable in foods, etc. It is desirable that the materials other than phytin used in the composition of the present invention do not impair the stability of phytin, and furthermore, it is desirable that they do not impair the intended effect of the composition of the present invention.

[0096] The composition of the present invention may be a food or drink or a pharmaceutical composition, and may be used as a food or drink such as a functional food, a food for specified health uses, a health food, a nutritional supplement, or a medical food.

[0097] In the present invention, "purines" is a general term for compounds that share a common structure called the purine backbone, and fulfill various functions in the body, such as transmitting genetic information as a component of nucleic acids. Purines include purine bases (e.g., adenine, guanine, hypoxanthine), purine nucleosides (e.g., adenosine, guanosine, inosine) in which a sugar is bound to a purine base, and purine nucleotides (e.g., adenylic acid (AMP), guanylic acid (GMP), inosinic acid (IMP)) in which a phosphate group is bound to a purine nucleoside. Most purines contained in foods exist as components of nucleic acids (nucleotide residues).

[0098] In the present invention, "purine absorption" means that the purine (purine base, purine nucleoside, purine nucleotide, or nucleic acid containing a purine nucleotide residue (e.g., oligonucleotide, polynucleotide)) is absorbed into the body via metabolism in the body depending on the form of the purine.

[0099] In the present invention, "inhibition of purine absorption" means a relative reduction in the amount of purines (e.g., dietary purines) absorbed into the body (e.g., absorbed from the intestinal tract). This "inhibition of purine absorption" includes, for example, inhibition of alkaline phosphatase and / or 5'-nucleotidase, thereby preventing the conversion of purine nucleotides to purine nucleosides (which results in a reduction in the amount of purines absorbed into the body).

[0100] In the present invention, the term "dietary purines" refers to purines derived from foods and beverages when they are ingested.

[0101] In the present invention, "purines absorbable from the intestinal tract" include purine bases and purine nucleosides.

[0102] In the present invention, "inhibition of purine nucleotide metabolism" means inhibition of the conversion of purine nucleotides to purine nucleosides.

[0103] In the present invention, "phosphatase inhibition" means inhibiting the activity of phosphatase involved in the metabolism of purines, and means, for example, inhibiting alkaline phosphatase and / or 5' nucleotidase.

[0104] In the present invention, "suppressing an increase in uric acid levels" means suppressing an excessive increase in uric acid levels, and includes, for example, lowering serum uric acid levels or alleviating the increase in those with high serum uric acid levels (including those who are normal but have high levels), maintaining serum uric acid levels in those with normal or low serum uric acid levels, and preventing or alleviating an increase in serum uric acid levels.

[0105] In one embodiment, the composition for suppressing an increase in uric acid level includes a single dose of phytin, in which the amount of phytin is 10 mg to 15 g in terms of phytic acid.

[0106] In the present invention, "improving blood pressure" means suppressing an excessive rise in blood pressure, and includes, for example, lowering blood pressure or alleviating the rise in blood pressure in a person with high blood pressure (including those who are normal but have high blood pressure), maintaining blood pressure in a person with normal blood pressure or a person with low blood pressure, preventing blood pressure from rising, or alleviating the rise in blood pressure.

[0107] In the present invention, "improving blood glucose levels" means suppressing excessive increases in blood glucose levels, and includes, for example, lowering blood glucose levels or alleviating increases in blood glucose levels in individuals with high blood glucose levels (including those who are normal but have high blood glucose levels), maintaining blood glucose levels in individuals with normal blood glucose levels or those with low blood glucose levels, preventing blood glucose levels from increasing, or alleviating increases in blood glucose levels.

[0108] In the present invention, "improvement of liver function" means improvement of liver function, and for example, the function can be indicated by an index (e.g., AST: aspartate aminotransferase). For example, "improvement of liver function" includes lowering or alleviating the rise in blood AST levels in individuals with high blood AST levels (including those who are normal but have high levels), maintaining blood AST levels in individuals with normal or low blood AST levels, and preventing or alleviating the rise in blood AST levels.

[0109] In the present invention, "serum iron adjustment" means preventing excessive increases or decreases in serum iron levels, and includes, for example, lowering serum iron levels or alleviating increases in serum iron levels in individuals with high serum iron levels (including those who are normal but have high levels), raising serum iron levels or alleviating decreases in serum iron levels in individuals with low serum iron levels (including those who are normal but have low levels), maintaining serum iron levels in individuals with normal serum iron levels, and preventing or alleviating increases or decreases in serum iron levels.

[0110] In the present invention, "promoting calcium absorption" means promoting calcium absorption from the intestinal tract.

[0111] In the present invention, "promoting calcium absorption" includes increasing the blood concentration of active vitamin D (1,25-(OH)2-D), which promotes calcium absorption from the intestinal tract.

[0112] The purine absorption-inhibiting composition, purine nucleotide metabolism-inhibiting composition, phosphatase-inhibiting composition, uric acid level increase-inhibiting composition, blood pressure-improving composition, blood glucose level-improving composition, liver function-improving composition, serum iron-regulating composition, or calcium absorption-promoting composition-reducing composition of the present invention can be formulated as a preparation for use in these prescribed uses (purine nucleotide metabolism inhibition, phosphatase inhibition, uric acid level increase-inhibiting composition, blood pressure improvement, blood glucose level improvement, liver function improvement, serum iron regulation, or calcium absorption promotion). The prescribed uses of the preparations may be indicated on the body of the preparation, packaging, instructions, pamphlets, containers, promotional materials, point-of-sale promotional materials such as POP, other documents, or electromagnetic means (such as the Internet). For example, the prescribed uses or expressions evocative of or suggestive of the prescribed uses are also included within the scope of the present invention: pharmaceuticals (including quasi-drugs); functional foods whose efficacy has been approved by a designated organization, such as foods for specified health uses, foods with nutrient functions, and foods with functional claims; and ordinary foods and beverages.

[0113] For example, with regard to the composition for inhibiting purine absorption or the composition for inhibiting an increase in uric acid levels of the present invention, foods and beverages that describe expressions that evoke or suggest the inhibition of purine absorption or the inhibition of an increase in uric acid levels, such as "for those who are concerned about purines in their meals," "fights purines," "for those who tend to eat meals high in purines," and "for those who are concerned about uric acid levels after meals," are also included within the scope of the present invention.

[0114] With regard to the blood pressure improving composition of the present invention, foods, beverages, etc. that describe expressions that evoke or suggest blood pressure improvement, such as "suitable for those with high blood pressure," "supports healthy blood pressure," "has the effect of lowering high blood pressure," "for those concerned about blood pressure," "maintains normal blood pressure," and "improves blood pressure," are also included within the scope of the present invention.

[0115] With regard to the blood glucose level-improving composition of the present invention, foods and beverages etc. that describe expressions that evoke or suggest improvement in blood glucose levels, such as "suitable for those concerned about blood glucose levels," "gentles the rise in blood glucose levels," "maintains high blood glucose levels to normal," and "for those with high blood glucose levels," are also included within the scope of the present invention.

[0116] With regard to the liver function improving composition of the present invention, foods, beverages, etc. containing expressions that evoke / infer liver function improvement, such as "maintain a healthy liver" or "for those with higher liver function values," are also included within the scope of the present invention.

[0117] With regard to the serum iron adjusting composition of the present invention, foods and beverages that include expressions that evoke or suggest serum iron adjustment, such as "for those concerned about iron deficiency" or "for treating anemia," are also included within the scope of the present invention.

[0118] With regard to the calcium absorption-promoting composition of the present invention, foods, beverages, etc. that describe expressions that evoke or suggest calcium absorption promotion, such as "helpful for bone health," "maintains bone components," "helps bone metabolism," "maintains strong bones," and "prevents osteoporosis," are also included within the scope of the present invention.

[0119] The subject to which the composition of the present invention is administered is not particularly limited, but is preferably a human. The composition of the present invention can be administered to a person concerned about uric acid levels, blood pressure, blood glucose levels, liver function, anemia, or bone health, as well as by healthy people for daily health promotion.

[0120] Production Example 1: 108 mL of a commercially available phytic acid solution (trade name: Phytic Acid (IP6), Tsuno Foods Co., Ltd.) (containing 75 g of phytic acid) was mixed with 1,362 mL of Milli-Q water and stirred thoroughly for several minutes at a water temperature of 40-60°C. A magnetic stirrer was used for stirring (same below). 8.4 g of Ca(OH) ２ The mixture was stirred thoroughly at a water temperature of 35-55°C for 10-40 minutes until completely dissolved. ２ The mixture was then stirred thoroughly for approximately 10-40 minutes at a water temperature of 30-50°C. Finally, 30 mL of 3.79 M KOH / NaOH aqueous solution was added in small portions and stirred thoroughly for approximately 10-40 minutes at a water temperature of 25-45°C. To the resulting mixture, 86 mL of a freshly prepared phytic acid solution (product name: Phytic Acid (IP6), Tsuno Foods Co., Ltd.) (containing 60 g of phytic acid) was mixed with 1114 mL of Milli-Q water and stirred thoroughly. Hydrochloric acid was added to adjust the pH to 4.0±0.2, and the mixture was stirred thoroughly for 30-120 minutes. 84.0 g of dextrin was added to the resulting mixture and stirred thoroughly for 30-90 minutes. The mixture was then placed in an appropriate container and lyophilized to obtain phytin (1.8 mol of phytic acid, with a Mg:K:Na:Ca ratio of 4:1:1:1 (mol)).

[0121] Test Example 1 Solubility Phytic acid and various minerals were mixed in water, and the solubility of each phytin having a predetermined molar ratio was examined based on the turbidity of the resulting mixture. <Test Method> (Sample Preparation) Ca(OH) as a calcium source was placed in a 50 mL PP tube (IWAKI) at room temperature of 20 to 25°C. ２ (Inoue Lime Industry Co., Ltd.), Mg(OH) as a magnesium source ２(Tomita Pharmaceutical Co., Ltd.), KOH (Nippon Soda Co., Ltd.) as a potassium source, and NaOH (TOSOH Corporation) as a sodium source were added according to the table below. 0.426 mL of commercially available phytic acid solution (trade name: Phytic Acid (IP6), Tsuno Foods Co., Ltd.) (containing 0.296 g of phytic acid) was then added, followed by distilled water (Otsuka Pharmaceutical Factory, Inc.) to bring the total volume to 30 mL. After 30 seconds of stirring using a vortex mixer, the solution was sonicated (ASONE) for 60 seconds. This stirring and sonication procedure was repeated three times. (Turbidity Measurement and Visual Test) Each sample obtained above was stirred for 30 seconds, and turbidity measurements (Molecular Devices) were performed according to the solubility test method in the Official Specification of Food Additives (9th edition, 2018). The absorbance at 600 nm of the "almost transparent" standard solution was 0.008. The samples were visually observed to evaluate the presence or absence of phytin precipitation. ◯: No precipitation. ×: Presence of precipitation. Samples with an absorbance of 0.008 or less and no precipitation observed by visual observation were rated as "water-soluble." All other samples were rated as "water-insoluble." The results are shown in the table below and in Figure 1.

[0122]

[0123] Discussion When the amount of calcium per 1.8 moles of phytic acid is x moles and the amount of magnesium per 1.8 moles of phytic acid is y moles, all phytins that satisfy the relationship 1.4x + y ≦ 5.4 are water-soluble.

[0124] Production Example 2 Each sample obtained in Test Example 1 was freeze-dried to obtain each phytin (powder) having the molar ratio shown in Table 1.

[0125] Test Example 2: Effect of the molar ratio of minerals in phytin on purine nucleotide metabolism inhibitory activity (Sample preparation) Ca(OH) was added as a calcium source to a 50 mL PP tube (IWAKI) in the molar ratio shown in Table 2 below. ２ (Inoue Lime Industry Co., Ltd.), Mg(OH) as a magnesium source ２(Tomita Pharmaceutical Co., Ltd.), KOH (Nippon Soda Co., Ltd.) as a potassium source, and NaOH (TOSOH Corporation) as a sodium source were weighed, and 0.426 mL of phytic acid solution (trade name: Phytic Acid (IP6), Tsuno Foods Industry Co., Ltd.) (containing 0.296 g of phytic acid) was added. Distilled water (Otsuka Pharmaceutical Factory, Inc.) was added to make a 30 mL solution. The mixture was stirred for 30 seconds using a vortex mixer and then ultrasonicated (ASONE) for 60 seconds to prepare sample solutions containing phytin with various mineral compositions. As a positive control, a sample solution containing commercially available phytin (Phytin (IP6), Tsuno Foods Industry Co., Ltd.) was also prepared at a concentration equivalent to the phytic acid content of the other samples. (Turbidity Measurement and Visual Test) Each sample solution obtained above was stirred for 30 seconds, and turbidity measurements (Molecular Devices) were performed according to the solubility test method in the Official Standards of Food Additives (9th edition, 2018). The absorbance at 600 nm of the "almost transparent" standard solution was 0.008. The samples were visually observed to evaluate the presence or absence of phytin precipitation. Samples with an absorbance of 0.008 or less and no visible precipitation were rated as "water-soluble." All other samples were rated as "water-insoluble." The results are shown in Table 2. (Test Method for Purine Nucleotide Metabolism Inhibitory Activity) Rat small intestine powder (CLEA Japan, Inc.) was prepared in assay buffer to 100 mg / mL to serve as the enzyme solution. Inosine monophosphate (Sigma-Aldrich) was prepared in assay buffer to 9 mM to serve as the substrate solution. The enzyme reaction was carried out using a 96-well plate (Thermo Fisher Scientific) using the following method. Sample solution (100 μL / well), substrate solution (100 μL / well), and enzyme solution (100 μL / well) were added, and the enzyme reaction was carried out at 37°C for 30 minutes. A 20 μL aliquot of the reaction solution was transferred to a Multiscreen HTS HV (Merck Millipore), and a stop solution (0.33 M HClO4, 180 μL / well) was added to terminate the reaction. The mixture was centrifuged (1080 × g, 10 minutes, room temperature), and the filtrate was used as a sample for high-performance liquid chromatography (HPLC). The HPLC analysis conditions are shown below.Detector: SPD-M30A (Shimadzu Corporation) Column: COSMOSIL PAQ (4.6 mm ID x 150 mm, Nakarai Tesque, Inc.) Mobile phase: 50 mM KH2PO4 (pH 7.5) Flow rate: 1.0 mL / min, detection wavelength: 254 nm, column temperature: 35°C Sample injection amount: 10 μL, pH: 6.4 The results are shown in Figures 2-1 to 2-5.

[0126]

[0127] Discussion: A comparative study of enzyme inhibitory activity with phytic acid (trade name: Phytic Acid (IP6), Tsuno Foods Co., Ltd.) was conducted under conditions where the enzyme inhibitory activity of phytic acid is approximately 30% and the inhibitory activity of phytin is significantly lower than that of phytic acid. A significant increase in activity was observed with Mg-01, which contained 4 moles of magnesium per 1.8 moles of phytic acid. On the other hand, a significant decrease in inhibitory activity was observed in Mg-02 to Mg-06, which contained 6, 8, 12, 16, and 20 moles of magnesium, respectively, inversely proportional to the molar ratio of magnesium. Increased activity was observed with Ca-01 to Ca-04, which contained 1, 2, 4, and 8 moles of calcium per 1.8 moles of phytic acid, respectively. Results for Na-01 to Na-08, which contained 0, 1, 2, 4, 6, 12, 16, and 20 moles of sodium per 1.8 moles of phytic acid, respectively, showed no effect of sodium addition on inhibitory activity. The results for K-01 to K-07, which contained 0, 1, 4, 8, 12, 16, and 20 moles of potassium per 1.8 moles of phytic acid, respectively, showed no effect of potassium addition on inhibitory activity. DE2, which contained 1 mole of calcium as the only mineral component per 1.8 moles of phytic acid, showed a significant increase in inhibitory activity of approximately 1.9 times greater than that of phytic acid. DE3, which contained 4 moles of magnesium as the only mineral component per 1.8 moles of phytic acid, showed an increase in inhibitory activity of approximately 1.3 times greater than that of phytic acid. DE4, which contained 1 mole of sodium as the only mineral component per 1.8 moles of phytic acid, showed no change in inhibitory activity compared to phytic acid. DE5, which contained 1 mole of potassium as the only mineral component per 1.8 moles of phytic acid, showed no change in inhibitory activity compared to phytic acid. The enzyme inhibitory activities of the water-soluble phytins Mg-01, Ca-01, K-02, Na-02, DE1 (which have the same composition), K-01, Na-01, Na-03, DE2, and DE3 were higher than those of phytic acid.

[0128] Test Example 3: Stability (Deliquescence) of Commercially Available Products Commercially available powdered phytic acid (trade name: Powdered Phytic Acid, Fuso Chemical Co., Ltd.) and commercially available phytin (trade name: Phytin (IP6), Tsuno Foods Co., Ltd., powder) were left at humidities of 11.2%, 32.8%, 52.9%, 75.3%, and 97.3% for 64 hours, and their states were visually observed. Each test humidity environment was created by placing saturated aqueous solutions of lithium chloride (equilibrium relative humidity (ERH): 11.2), magnesium chloride (ERH: 32.8), magnesium nitrate (ERH: 52.9), sodium chloride (ERH: 75.3), and potassium sulfate (ERH: 97.3) in a desiccator, installing a thermo-hygrometer, and allowing the desiccator to stand at a temperature of 25°C. As a result, the powdered phytic acid solidified at a humidity of 32.8% and liquefied into a starch syrup-like state at humidity levels of 52.9% or higher. On the other hand, no change was observed in phytin under any humidity conditions.

[0129] Test Example 4: Stability (Deliquescence) (Sample Preparation) A 50 mL PP tube (IWAKI) was charged with Ca(OH) as a calcium source in the molar ratio shown in Table 3 below. ２ (Inoue Lime Industry Co., Ltd.), Mg(OH) as a magnesium source ２(Tomita Pharmaceutical Co., Ltd.), KOH (Nippon Soda Co., Ltd.) as a potassium source, and NaOH (TOSOH Corporation) as a sodium source were weighed, and 0.426 mL of phytic acid (Phytic Acid (IP6), Tsuno Foods Industry Co., Ltd.) (containing 0.296 g of phytic acid) was added. Distilled water (Otsuka Pharmaceutical Factory, Inc.) was added to make a 30 mL solution. The solution was stirred for 30 seconds using a vortex mixer and then sonicated (ASONE) for 60 seconds. This stirring and sonication procedure was repeated three times. The pH was then adjusted to 4.0 ± 0.2 using hydrochloric acid and the solution was pre-frozen at −80°C. Phytin was completely powdered using a freeze dryer and used as a test sample. Phytic acid (powder) prepared using the above procedure without adding any mineral components and commercially available powdered phytic acid (trade name: Powdered Phytic Acid, Fuso Chemical Co., Ltd.) were used as positive controls. Furthermore, commercially available phytin (Phytin (IP6), Tsuno Foods Co., Ltd.) was used as a negative control. (Test method) A saturated aqueous solution of sodium chloride was placed in a desiccator and allowed to stand at a temperature of 25°C until the humidity reached 75.3%. Approximately 200 mg of phytin with various mineral compositions, including phytins in the range of water solubility (specifically, Samples 2, 3, 6-9, and 12-21) that were determined to be water soluble based on the results of Test Example 1, was placed in a Petri dish (MS-11350: SUMILON) and allowed to stand for 64 hours in the desiccator. After standing, if a visual change in state occurred, such as the entire sample becoming like a starch syrup, it was judged as "present" deliquescence; if partial deliquescence or solidification was observed, it was judged as "partially present" deliquescence; and if no change was observed, it was judged as "absent."

[0130] (Results) The results are shown in Table 3. Phytic acid and powdered phytic acid, which were used as positive controls, deliquesced and became starch syrup-like. On the other hand, the phytins in samples 1 to 21 either did not deliquesce or only partially deliquesced or solidified, indicating that they were more stable in terms of deliquescence than phytic acid.

[0131] Test Example 5: Long-Term Storage Stability (Sample Preparation) A long-term storage stability test was conducted on the water-soluble phytin obtained by the method of Production Example 1 (the molar ratio of Mg:Ca:Na:K relative to 1.8 moles of phytic acid was 4:1:1:1, and the dextrin concentration was 67%). Specifically, the water activity of the phytin was measured over time up to 3 months when stored in a stability tester (ETAC LABONIC LX330, Kusumoto Chemicals) at a temperature of 25°C and a humidity of 60%, and when stored in an incubator (Incubator IS82, Yamato Scientific) at a temperature of 40°C and a humidity of 75%. The water activity measurement was performed at a temperature of 25°C using a measuring device (LabMster-aw Basic, Novasina). The state of the sample was also visually observed. The storage conditions, water activity, and properties were shown in Table 4 below. The water activity of water-soluble phytin before storage under high humidity conditions was 0.020, but it increased slightly over time to 0.027-0.030 when stored at 25°C and 60% humidity, and to 0.034-0.047 when stored at 40°C and 75% humidity. However, these values ​​are less than one-tenth of the water activity of 0.5 or less, which is the water activity at which microorganisms generally do not grow in food, i.e., when not absorbing moisture, and therefore it can be said that the moisture absorption of this phytin is slight. Furthermore, regarding its properties, it was a white powder and did not deliquesce. These results demonstrate that this phytin can remain stable in powder form for a long period of time.

[0132] The phytin of the present invention is particularly useful in preparations that require good water solubility, such as liquid preparations and granules that are dissolved in water and ingested when used.

Claims

1. A water-soluble phytic acid containing (A) calcium and / or (B) magnesium, wherein when the amount of substance of (A) calcium per 1.8 moles of phytic acid is x moles and the amount of substance of (B) magnesium is y moles, 1.4x + y ≤ 5.4 (x ≥ 0, y ≥ 0, provided that neither x nor y is 0), phytic acid.

2. A water-soluble phytic acid containing (A) calcium and / or (B) magnesium, wherein in the phytic acid, when the amount of substance of (A) calcium per 1.8 moles of phytic acid is x moles and the amount of substance of (B) magnesium is y moles, 0 ≤ x ≤ 2, 0 ≤ y ≤ 6, and neither x nor y is 0, phytic acid.

3. The phytic acid according to claim 1 or 2, wherein x + y > 0.

5.

4. The phytic acid according to claim 1 or 2, wherein 0.3 ≤ x ≤ 1.07 and 3.9 ≤ y ≤ 4.

98.

5. The phytic acid according to claim 1 or 2, wherein 0.65 ≤ x ≤ 1.07 and 3.9 ≤ y ≤ 4.

4.

6. The phytic acid according to claim 2, wherein 0.9 ≤ x ≤ 1.1 and 3.9 ≤ y ≤ 4.

1.

7. The phytic acid according to claim 1 or 2, further containing (C) potassium and / or (D) sodium.

8. The phytic acid according to claim 7, wherein when the amount of substance of (C) potassium per 1.8 moles of phytic acid is p moles and the amount of substance of (D) sodium is q moles, 0 ≤ p ≤ 4, 0 ≤ q ≤ 6, and neither p nor q is 0.

9. A composition containing the phytic acid according to claim 1 or 2.

10. A composition for suppressing purine absorption containing the phytic acid according to claim 1 or 2.

11. The composition for suppressing purine absorption according to claim 10, wherein the purine absorption is absorption from the intestinal tract.

12. A composition for inhibiting purine nucleotide metabolism containing the phytic acid according to claim 1 or 2.

13. A composition for inhibiting phosphatase containing the phytic acid according to claim 1 or 2.

14. A composition for suppressing an increase in uric acid value containing the phytic acid according to claim 1 or 2.

15. A composition for improving blood pressure containing the phytic acid according to claim 1 or 2.

16. A composition for improving blood glucose value containing the phytic acid according to claim 1 or 2.

17. A high-calcium urine prevention composition containing phytic acid according to claim 1 or 2.

18. A lipid improvement composition containing phytic acid according to claim 1 or 2.

19. The composition according to claim 1 or 2, which is a solid preparation.

20. A method for improving the solubility of phytic acid in water, which includes adding a calcium source and a magnesium source in the presence of water to phytic acid. When the amount of substance of (A) calcium added per 1.8 moles of phytic acid is x moles and the amount of substance of (B) magnesium is y moles, 1.4x + y ≤ 5.4 (x ≥ 0, y ≥ 0, provided that both x and y are not 0).

21. Phytic acid; and A calcium source and / or a magnesium source; A mixing step of mixing in the presence of water, and A drying step of drying the obtained mixture are included, In the mixture, when the amount of substance of (A) calcium per 1.8 moles of phytic acid is x moles and the amount of substance of (B) magnesium is y moles, 1.4x + y ≤ 5.4 (x ≥ 0, y ≥ 0, provided that both x and y are not 0). A method for producing phytic acid.

22. Phytic acid; and A magnesium source and / or a calcium source; A mixing step of mixing in the presence of water, and A drying step of drying the obtained mixture are included, In the mixture, when the amount of substance of (A) calcium per 1.8 moles of phytic acid is x moles and the amount of substance of (B) magnesium is y moles, 0 ≤ x ≤ 2, 0 ≤ y ≤ 6, and both x and y are not 0. A method for producing phytic acid.

23. The method according to any one of claims 20 to 22, wherein x + y > 0.

5.

24. The method according to any one of claims 20 to 22, wherein 0.3 ≤ x ≤ 1.07 and 3.9 ≤ y ≤ 4.

98.

25. The method according to any one of claims 20 to 22, wherein 0.65 ≤ x ≤ 1.07 and 3.9 ≤ y ≤ 4.

4.

26. The method according to claim 22, wherein 0.9 ≤ x ≤ 1.1 and 3.9 ≤ y ≤ 4.

1.

27. In the mixing step, Phytic acid; and A magnesium source and / or a calcium source; are mixed in the presence of water and an excipient. The production method according to claim 21 or 22.

28. In the mixing step, Phytic acid; A magnesium source and / or a calcium source; and A potassium source and / or a sodium source are The production method according to claim 21 or 22, which is mixed in the presence of water.

29. In the mixing step Phytic acid; A magnesium source and / or a calcium source; and A potassium source and / or a sodium source: The production method according to claim 21 or 22, which is mixed in the presence of water and an excipient.

30. In the mixture, when the amount of substance of (C) potassium per 1.8 moles of phytic acid is p moles and the amount of substance of (D) sodium is q moles, 0 ≦ p ≦ 4, 0 ≦ q ≦ 6, and both p and q are not 0, the production method according to claim 28.

31. The production method according to claim 27, wherein the excipient is selected from dextrin, starches, cellulose, saccharides, and any combination thereof.

32. A purine absorption inhibitory composition containing water-soluble phytic acid containing only calcium as a mineral component.

33. The purine absorption inhibitory composition according to claim 32, wherein the molar ratio in the water-soluble phytic acid is phytic acid:calcium = 1.8:0.1 to 4.0 (moles).

34. Use of the phytic acid according to claim 1 or 2 in the production of a purine absorption inhibitory composition, a purine nucleotide metabolism inhibitory composition, a phosphatase inhibitory composition, a uric acid level increase inhibitory composition, a blood pressure improving composition, a blood glucose level improving composition, a liver function improving composition, a serum iron regulating composition, a calcium absorption promoting composition, a hypercalciuria preventing composition, a lipid improving composition.

35. A composition containing the phytic acid according to claim 1 or 2 for use in purine absorption inhibition, purine nucleotide metabolism inhibition, phosphatase inhibition, uric acid level increase inhibition, blood pressure improvement, blood glucose level improvement, liver function improvement, serum iron regulation, calcium absorption promotion, hypercalciuria prevention, or lipid improvement.